FI68818C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,3-bentsoxazin-2,4-dioner - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,3-bentsoxazin-2,4-dioner Download PDFInfo
- Publication number
- FI68818C FI68818C FI792632A FI792632A FI68818C FI 68818 C FI68818 C FI 68818C FI 792632 A FI792632 A FI 792632A FI 792632 A FI792632 A FI 792632A FI 68818 C FI68818 C FI 68818C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- benzoxazine
- preparation
- ortho
- chloro
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims description 10
- OAYRYNVEFFWSHK-UHFFFAOYSA-N carsalam Chemical class C1=CC=C2OC(=O)NC(=O)C2=C1 OAYRYNVEFFWSHK-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- GBNWQQUVAPTWKO-UHFFFAOYSA-N 6-chloro-3-methyl-1,3-benzoxazine-2,4-dione Chemical compound C1=C(Cl)C=C2C(=O)N(C)C(=O)OC2=C1 GBNWQQUVAPTWKO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229960000581 salicylamide Drugs 0.000 claims description 3
- GMFBXDUNANTIIL-UHFFFAOYSA-N 5-chloro-2-hydroxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC(Cl)=CC=C1O GMFBXDUNANTIIL-UHFFFAOYSA-N 0.000 claims description 2
- 229910014033 C-OH Inorganic materials 0.000 claims description 2
- 229910014570 C—OH Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 150000002513 isocyanates Chemical class 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- JNZZLCUTRFPQPJ-UHFFFAOYSA-N 6-bromo-3-methyl-1,3-benzoxazine-2,4-dione Chemical compound C1=C(Br)C=C2C(=O)N(C)C(=O)OC2=C1 JNZZLCUTRFPQPJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FNXRPOPDYIZQHW-UHFFFAOYSA-N 6-chloro-3-(2-phenoxyphenyl)-1,3-benzoxazine-2,4-dione Chemical compound O=C1C2=CC(Cl)=CC=C2OC(=O)N1C1=CC=CC=C1OC1=CC=CC=C1 FNXRPOPDYIZQHW-UHFFFAOYSA-N 0.000 description 1
- GOMXAFKCHRQJPQ-UHFFFAOYSA-N 6-chloro-3-(2-thiophen-2-yloxyphenyl)-1,3-benzoxazine-2,4-dione Chemical compound ClC=1C=CC2=C(C(N(C(O2)=O)C2=C(C=CC=C2)OC=2SC=CC=2)=O)C=1 GOMXAFKCHRQJPQ-UHFFFAOYSA-N 0.000 description 1
- HKZCOWRJCWNNFP-UHFFFAOYSA-N 6-chloro-3-(furan-2-ylmethyl)-1,3-benzoxazine-2,4-dione Chemical compound O=C1C2=CC(Cl)=CC=C2OC(=O)N1CC1=CC=CO1 HKZCOWRJCWNNFP-UHFFFAOYSA-N 0.000 description 1
- RUSRJCQXSADYBI-UHFFFAOYSA-N 6-chloro-3-ethyl-1,3-benzoxazine-2,4-dione Chemical compound C1=C(Cl)C=C2C(=O)N(CC)C(=O)OC2=C1 RUSRJCQXSADYBI-UHFFFAOYSA-N 0.000 description 1
- OAJNFZRAWNMFEC-UHFFFAOYSA-N 6-chloro-3-propyl-1,3-benzoxazine-2,4-dione Chemical compound C1=C(Cl)C=C2C(=O)N(CCC)C(=O)OC2=C1 OAJNFZRAWNMFEC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- JWOLLWQJKQOEOL-UHFFFAOYSA-N OOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOO JWOLLWQJKQOEOL-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ZEHGKSPCAMLJDC-UHFFFAOYSA-M acetylcholine bromide Chemical compound [Br-].CC(=O)OCC[N+](C)(C)C ZEHGKSPCAMLJDC-UHFFFAOYSA-M 0.000 description 1
- 229940080018 acetylcholine injection Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- XBECFEJUQZXMFE-UHFFFAOYSA-N n-(4-aminobutyl)acetamide;hydrochloride Chemical compound Cl.CC(=O)NCCCCN XBECFEJUQZXMFE-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7824674A FR2434158A1 (fr) | 1978-08-25 | 1978-08-25 | Nouveaux derives de 1,3-benzoxazine-2,4-dione, leur preparation et leur application en tant que medicaments |
| FR7824674 | 1978-08-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI792632A7 FI792632A7 (fi) | 1980-02-26 |
| FI68818B FI68818B (fi) | 1985-07-31 |
| FI68818C true FI68818C (fi) | 1985-11-11 |
Family
ID=9212085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI792632A FI68818C (fi) | 1978-08-25 | 1979-08-23 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,3-bentsoxazin-2,4-dioner |
Country Status (25)
| Country | Link |
|---|---|
| JP (1) | JPS5533484A (de) |
| AR (1) | AR222494A1 (de) |
| AT (1) | AT373591B (de) |
| BE (1) | BE878395A (de) |
| BG (1) | BG30929A3 (de) |
| CA (1) | CA1128511A (de) |
| CH (1) | CH643548A5 (de) |
| CS (1) | CS208131B2 (de) |
| DD (1) | DD145534A5 (de) |
| DE (1) | DE2934166A1 (de) |
| EG (1) | EG14355A (de) |
| ES (1) | ES481856A1 (de) |
| FI (1) | FI68818C (de) |
| FR (1) | FR2434158A1 (de) |
| GB (1) | GB2031410B (de) |
| GR (1) | GR69619B (de) |
| HU (1) | HU182916B (de) |
| IL (1) | IL58096A (de) |
| NL (1) | NL7906408A (de) |
| PL (1) | PL116771B1 (de) |
| PT (1) | PT70107A (de) |
| RO (1) | RO78156A (de) |
| SE (1) | SE446865B (de) |
| SU (1) | SU797576A3 (de) |
| YU (1) | YU40849B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263657B2 (en) | 2000-12-18 | 2012-09-11 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
| WO2003103656A1 (ja) * | 2002-06-06 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ｏ−置換ヒドロキシアリール誘導体 |
| KR101054562B1 (ko) | 2002-06-06 | 2011-08-04 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 항알레르기약 |
| CN108658887B (zh) * | 2018-06-20 | 2022-04-05 | 中南大学 | 苯并[d][1,3]噁嗪-2,4(1H)-二酮衍生物及其合成方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2476559A (en) * | 1946-10-01 | 1949-07-19 | Gen Aniline & Film Corp | Oxazine diones |
| DE1153375B (de) * | 1960-05-25 | 1963-08-29 | Thomae Gmbh Dr K | Verfahren zur Herstellung von Benzoxazin-(1, 3)-dionen-(2, 4) |
| GB1069367A (en) * | 1964-10-01 | 1967-05-17 | Aspro Nicholas Ltd | Improvements in or relating to the production of 1:3-benzoxazine-2:4-dione |
| CH459211A (de) * | 1965-01-25 | 1968-07-15 | Robapharm Ag | Verfahren zur Herstellung von neuen basischen Derivaten des Dihydro-1,3-benzoxazin-2,4-dions |
-
1978
- 1978-08-25 FR FR7824674A patent/FR2434158A1/fr active Granted
-
1979
- 1979-06-06 ES ES481856A patent/ES481856A1/es not_active Expired
- 1979-08-21 DD DD79215096A patent/DD145534A5/de not_active IP Right Cessation
- 1979-08-22 RO RO7998518A patent/RO78156A/ro unknown
- 1979-08-22 HU HU79PO694A patent/HU182916B/hu not_active IP Right Cessation
- 1979-08-22 BG BG044725A patent/BG30929A3/xx unknown
- 1979-08-22 GR GR52886A patent/GR69619B/el unknown
- 1979-08-22 GB GB7929266A patent/GB2031410B/en not_active Expired
- 1979-08-22 PL PL1979217893A patent/PL116771B1/pl unknown
- 1979-08-22 CA CA334,287A patent/CA1128511A/fr not_active Expired
- 1979-08-23 AR AR277829A patent/AR222494A1/es active
- 1979-08-23 PT PT70107A patent/PT70107A/pt unknown
- 1979-08-23 BE BE0/196852A patent/BE878395A/fr not_active IP Right Cessation
- 1979-08-23 YU YU2073/79A patent/YU40849B/xx unknown
- 1979-08-23 SU SU792804596A patent/SU797576A3/ru active
- 1979-08-23 IL IL58096A patent/IL58096A/xx not_active IP Right Cessation
- 1979-08-23 FI FI792632A patent/FI68818C/fi not_active IP Right Cessation
- 1979-08-23 JP JP10764779A patent/JPS5533484A/ja active Pending
- 1979-08-23 DE DE19792934166 patent/DE2934166A1/de not_active Ceased
- 1979-08-23 AT AT0568379A patent/AT373591B/de not_active IP Right Cessation
- 1979-08-24 NL NL7906408A patent/NL7906408A/nl not_active Application Discontinuation
- 1979-08-24 SE SE7907067A patent/SE446865B/sv not_active IP Right Cessation
- 1979-08-24 CH CH773579A patent/CH643548A5/fr not_active IP Right Cessation
- 1979-08-24 CS CS795769A patent/CS208131B2/cs unknown
- 1979-08-27 EG EG520/79A patent/EG14355A/xx active
Also Published As
| Publication number | Publication date |
|---|---|
| FI792632A7 (fi) | 1980-02-26 |
| BG30929A3 (bg) | 1981-09-15 |
| BE878395A (fr) | 1980-02-25 |
| DD145534A5 (de) | 1980-12-17 |
| EG14355A (en) | 1983-12-31 |
| GB2031410B (en) | 1982-12-01 |
| NL7906408A (nl) | 1980-02-27 |
| GR69619B (de) | 1982-07-06 |
| SU797576A3 (ru) | 1981-01-15 |
| PL116771B1 (en) | 1981-06-30 |
| RO78156A (ro) | 1982-02-01 |
| AR222494A1 (es) | 1981-05-29 |
| DE2934166A1 (de) | 1980-02-28 |
| CA1128511A (fr) | 1982-07-27 |
| FR2434158B1 (de) | 1985-05-03 |
| YU207379A (en) | 1983-02-28 |
| PT70107A (fr) | 1979-09-01 |
| SE446865B (sv) | 1986-10-13 |
| FR2434158A1 (fr) | 1980-03-21 |
| PL217893A1 (de) | 1980-04-21 |
| CH643548A5 (fr) | 1984-06-15 |
| SE7907067L (sv) | 1980-02-26 |
| FI68818B (fi) | 1985-07-31 |
| CS208131B2 (en) | 1981-08-31 |
| IL58096A0 (en) | 1979-12-30 |
| YU40849B (en) | 1986-06-30 |
| JPS5533484A (en) | 1980-03-08 |
| IL58096A (en) | 1982-12-31 |
| HU182916B (en) | 1984-03-28 |
| ES481856A1 (es) | 1980-02-16 |
| ATA568379A (de) | 1983-06-15 |
| AT373591B (de) | 1984-02-10 |
| GB2031410A (en) | 1980-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4182774A (en) | Method of inhibiting blood platelet aggregation with 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof | |
| US4370338A (en) | Medicament based on 2-amino-6-trifluoromethoxy-benzothiazole | |
| DE2513157C2 (de) | ||
| HU202243B (en) | Process for producing (cycloalkylamino)-methylene-bis(phosphoric acid) derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| SU805948A3 (ru) | Способ получени -аминофосфонистыхКиСлОТ | |
| DK154287B (da) | Analogifremgangsmaade til fremstilling af triglycerider | |
| JPS5927357B2 (ja) | 新規チアゾ−ル誘導体 | |
| JPS63192758A (ja) | １‐（４‐ヒドロキシ‐３，５‐ジ‐ｔｅｒｔ．‐ブチルベンゾイル）ホモピペラジンおよびその誘導体 | |
| FI68818B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,3-bensoxazin-2,4-dioner | |
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| US3268582A (en) | Phenylalkyl-carboxylic acid amides | |
| IE891908L (en) | Novel esters | |
| DE2804576A1 (de) | Phenylamidin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| US3590041A (en) | Novel halo-substituted cinnamic acid heterocyclic amides | |
| US3377241A (en) | Certain diacyl derivatives of phloroglucinol as anthelmintics | |
| US3709911A (en) | ((thenylidene amino)oxy)alkyl carboxylic acids and salts and esters thereof | |
| PT100216B (pt) | N-{{4,5-di-hidroxi- e 4,5,8-tri-hidroxi-9,10-di-hidro-9,10-dioxo-2-antracentil} carbonil}-aminoacidos uteis na terapia de afeccoes osteoarticulares, processo para a sua preparacao e composicoes farmaceuticas que os contem | |
| FI66607B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2-5,6-dianhydro-hexitoler | |
| US4431664A (en) | Compound with antiulcerogenic activity, process for the preparation thereof and pharmaceutical composition therefrom | |
| HU182705B (en) | Process for producing substituted triaryl-tiazole-derivatives | |
| SU1447283A3 (ru) | Способ получени конденсированных производных @ S-триазина | |
| HU195803B (en) | Process for preparing new, substituted phenyl-piperazine derivatives and pharmaceutical compositions containing such compounds | |
| US3862226A (en) | Bis-{8 beta-(4-N,N-diacetylaminophenoxy)ethyl{9 ether | |
| US20080280964A1 (en) | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | |
| US3821415A (en) | Heterocyclic compounds in pharmaceutical compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: PROVESAN S.A. |